The impact of immunisation goes beyond health – it is about prosperity, security, and economic development. Ensuring equitable access to vaccines is a global priority, and the European Union (EU) plays a leading role in this effort.
In 2003, the EU first partnered up with Gavi, the Vaccine Alliance, to strengthen global health systems and has continued its successful collaboration ever since.
The Gavi 6.0 Pledging Summit
On 25 June 2025 in Brussels, the EU co-hosted – with the Gates Foundation – the Gavi 6.0 High-Level Pledging Summit, with the close support of other Gavi donors and implementing countries. The summit brought together a record number of global leaders from government, partner organisations, vaccine manufacturers, civil society, and the private sector, to secure crucial investments in vaccination programmes.
Donors pledged more than €7.7 billion towards a target budget of €10.2 billion for the 2026-2030 period. This included a total pledge of more than €2 billion from Team Europe – the EU and its Member States – collectively the largest donor to Gavi. Of this amount, the European Commission pledged €360 million.
Additional commitments were made, including
- €3.8 billion in complementary financing from development finance institutions
- up to €170.6 million in cost savings for Gavi-supported programmes announced by vaccine manufacturers
- more than €127 million in private sector partnerships focused on immunisation delivery
Gavi 6.0 goals (2026-2030)
Gavi’s 2026–2030 strategy (Gavi 6.0) is the final push to achieve global immunisation and health security targets ahead of the 2030 Sustainable Development Goals (SDG) deadline.
- 500 million children vaccinated
- More than 8 million lives saved
- €85.3 billion of estimated economic benefits
During the 2026-2030 period, Gavi aims to
- expand vaccine programmes and invest in emergency stockpiles to prevent outbreak-prone diseases at source
- ensure vaccine access for the world’s poorest countries in a possible future health crisis
- support local vaccine production through regional partnerships
The EU and Gavi
The EU has a long-standing partnership with Gavi, contributing over €3.2 billion since 2003 to advance global immunisation. This includes significant support through the COVAX Advance Market Commitment and the European Investment Bank financial instruments, part of the EU’s Global Coronavirus Response.
Together, the EU and its Member States – in a Team Europe approach – remain Gavi’s largest contributors, providing over €6.5 billion during the Gavi 5.0 strategic period (2021–2025). In September 2024, the Commission announced a new funding pledge of €260 million, for the years 2026–2027. The funds will contribute to Gavi’s 2030 goal to help protect 500 million children around the world, strengthen immunisation systems, and boost global health security by increasing readiness to respond to disease outbreaks.
The 2025 pledging Summit builds on the successful launch of Gavi’s 6.0 Investment Opportunity in June 2024 in Paris, co-hosted by France and the African Union, which raised $2.4 billion towards the $9 billion funding target of Gavi.
More information: European Commission.
Publicaciones relacionadas:
Vaccine (in)equity – no right of way for persons with disabilities in the EU
European Commission unveils EU vaccines strategy
European Commission authorises second safe and effective vaccine against COVID-19
New future-proof EU pharmaceutical policy
HERA secures up to 2 million doses of the monkeypox vaccine
Leave a Reply